Ramucirumab biosimilar (CTTQ) | Interleukin Related interleukin-related.com

Product Name :
Ramucirumab biosimilar (CTTQ)

Search keywords :
Ramucirumab

drugId :
null

Target Vo:
Vascular endothelial growth factor receptor 2

Target Vo Short Name :
VEGFR2

Moa_Name:
Vascular endothelial growth factor receptor 2 antagonists

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd

Active Company_Name :
Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd

Active Indication_Name:
Carcinoma, Non-Small-Cell Lung

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 1 Clinical

China Highest Status:
Phase 1 Clinical

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
GSK3 beta Mouse mAb custom synthesis
RbBP5 Rabbit mAb web
ATF3 Antibody: ATF3 Antibody is an unconjugated, approximately 20 kDa, rabbit-derived, anti-ATF3 polyclonal antibody. ATF3 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, IF expriments in human, mouse, and predicted: rat, chicken, dog, cow background without labeling.

Author: Interleukin Related

Related Posts